Bone is accrued and maintained primarily through the coupled actions of bone-forming osteoblasts and bone-resorbing osteoclasts. Cumulative in vitro studies indicated that proline-rich tyrosine kinase 2 (PYK2) is a positive mediator of osteoclast function and activity. However, our investigation of PYK2؊/؊ mice did not reveal evidence supporting an essential function for PYK2 in osteoclasts either in vivo or in culture. We find that PYK2؊/؊ mice have high bone mass resulting from an unexpected increase in bone formation. Consistent with the in vivo findings, mouse bone marrow cultures show that PYK2 deficiency enhances differentiation and activity of osteoprogenitor cells, as does expressing a PYK2-specific short hairpin RNA or dominantly interfering proteins in human mesenchymal stem cells. Furthermore, the daily administration of a small-molecule PYK2 inhibitor increases bone formation and protects against bone loss in ovariectomized rats, an established preclinical model of postmenopausal osteoporosis. In summary, we find that PYK2 regulates the differentiation of early osteoprogenitor cells across species and that inhibitors of the PYK2 have potential as a bone anabolic approach for the treatment of osteoporosis.human mesenchymal stem cell ͉ osteoclast ͉ osteoblast P roline-rich tyrosine kinase 2 (PYK2) and focal adhesion kinase (FAK) are nonreceptor tyrosine kinases, and together they constitute the focal adhesion kinase subfamily (1). Unlike FAK, PYK2 expression is relatively restricted, with highest levels in the brain and the hematopoietic system. PYK2Ϫ/Ϫ mice have been described previously and appear normally developed (2, 3). Characterization of the immune system of PYK2Ϫ/Ϫ animals revealed the absence of marginal zone B cells along and abnormal T cell-independent type II responses (2), as well as altered macrophage morphology, adhesion, and migration (3).Although PYK2 is expressed in both bone-forming osteoblasts and bone-resorbing osteoclasts, the skeletal phenotype of PYK2Ϫ/Ϫ mice has not been described. In vitro studies pointed to a positive role for PYK2 in osteoclast maturation and bone resorption. PYK2 localizes to the podosomes of osteoclasts (4), and, upon integrin binding, cell attachment, and actin ring formation, PYK2 associates with a variety of proteins including p130 CAS (5), Src (4), Cbl (6), integrins (4), gelsolin (7), and paxillin (8). Antisense depletion of PYK2 (9), but not the expression of a kinase inactive dominant negative mutant (10), blocked osteoclast spreading and bone resorption, indicating that PYK2 catalytic activity may be dispensable. The in vitro effects of bone anabolic stimuli suggested that PYK2 might have a positive role in osteoblasts as well. Treatment of osteoblast cells with fluoroaluminate led to increased PYK2 autophosphorylation, Src association, and kinase activity (11) and was associated with increased cell attachment and spreading (12). Likewise, in an anabolic model of mechanical loading, PYK2 autophosphorylation and kinase activity were stimulated in o...

E2F proteins control cell cycle progression by predominantly acting as either activators or repressors of transcription. How the antagonizing activities of different E2Fs are integrated by cis-acting control regions into a final transcriptional output in an intact animal is not well understood. E2F function is required for normal development in many species, but it is not completely clear for which genes E2F-regulated transcription provides an essential biological function. To address these questions, we have characterized the control region of the Drosophila PCNA gene. A single E2F binding site within a 100-bp enhancer is necessary and sufficient to direct the correct spatiotemporal program of G1-S-regulated PCNA expression during development. This dynamic program requires both E2F-mediated transcriptional activation and repression, which, in Drosophila, are thought to be carried out by two distinct E2F proteins. Our data suggest that functional antagonism between these different E2F proteins can occur in vivo by competition for the same binding site. An engineered PCNA gene with mutated E2F binding sites supports a low level of expression that can partially rescue the lethality of PCNA null mutants. Thus, E2F regulation of PCNA is dispensable for viability, but is nonetheless important for normal Drosophila development.

Steroid signaling underlies developmental processes in animals. Mutations that impair steroidogenesis in the fruit fly Drosophila melanogasterprovide tools to dissect steroid hormone action genetically. The widely used temperature-sensitive mutation ecdysoneless1(ecd1) disrupts production of the steroid hormone ecdysone, and causes developmental and reproductive defects. These defects cannot be satisfactorily interpreted without analysis of the ecdgene. Here, we show that ecd encodes an as yet functionally undescribed protein that is conserved throughout eukaryotes. The ecd1 conditional allele contains an amino acid substitution, whereas three non-conditional larval lethal mutations result in truncated Ecd proteins. Consistent with its role in steroid synthesis, Ecd is expressed in the ecdysone-producing larval ring gland. However, development of ecd-null early larval lethal mutants cannot be advanced by Ecd expression targeted to the ring gland or by hormone feeding. Cell-autonomous ecd function, suggested by these experiments, is evidenced by the inability of ecd– clones to survive within developing imaginal discs. Ecd is also expressed in the ovary, and is required in both the follicle cells and the germline for oocyte development. These defects, induced by the loss of ecd, provide the first direct evidence for a cell-autonomous function of this evolutionarily conserved protein.

Proline-rich tyrosine kinase 2 (PYK2) is a cytoplasmic, nonreceptor tyrosine kinase implicated in multiple signaling pathways. It is a negative regulator of osteogenesis and considered a viable drug target for osteoporosis treatment. The high-resolution structures of the human PYK2 kinase domain with different inhibitor complexes establish the conventional bilobal kinase architecture and show the conformational variability of the DFG loop. The basis for the lack of selectivity for the classical kinase inhibitor, PF-431396, within the FAK family is explained by our structural analyses. Importantly, the novel DFG-out conformation with two diarylurea inhibitors (BIRB796, PF-4618433) reveals a distinct subclass of non-receptor tyrosine kinases identifiable by the gatekeeper Met-502 and the unique hinge loop conformation of Leu-504. This is the first example of a leucine residue in the hinge loop that blocks the ATP binding site in the DFG-out conformation. Our structural, biophysical, and pharmacological studies suggest that the unique features of the DFG motif, including Leu-504 hinge-loop variability, can be exploited for the development of selective protein kinase inhibitors.Proline-rich tyrosine kinase 2 (PYK2) 2 and focal adhesion kinase (FAK) comprise the focal adhesion kinase subfamily of non-receptor tyrosine kinases. PYK2 and FAK are large multidomain proteins containing an N-terminal FERM domain, a central catalytic domain, and a C-terminal segment containing dual proline rich (PR) subdomains and a focal adhesion targeting (FAT) region (1, 2). While FAK is widely expressed, PYK2 expression is relatively restricted with highest levels in brain and the hematopoeitic system. Unlike FAK, optimal PYK2 activation is dependent on Ca 2ϩ mobilization. PYK2 (Ϫ/Ϫ) animals have been described previously, and develop normally (3, 4). Characterization of the immune system of PYK2(Ϫ/Ϫ) animals revealed the absence of marginal zone B-cells along with abnormal T-cell independent type II responses (4), and altered macrophage morphology, migration and signaling in response to cell attachment or chemokine treatment (3). These studies strengthen the link between PYK2 and signaling through chemokine and integrin receptors. In addition, PYK2(Ϫ/Ϫ) mice were shown to have increased susceptibility to diet-induced obesity and diabetes (5).Recently, the characterization of PYK2(Ϫ/Ϫ) mice showed a high bone mass phenotype resulting from increased osteogenesis and osteoblast activity. Using PYK2(Ϫ/Ϫ) mouse bone marrow cultures and hMSCs expressing a PYK2 shRNA, elimination or reduction of PYK2 protein levels resulted in significantly enhanced osteogeogenesis. Importantly, the daily administration of a pyrimidine-based PYK2 inhibitor, PF-431396, increased bone formation, and protected against bone loss in ovariectomized rats (6). PYK2(Ϫ/Ϫ) mice showed mild osteopetrosis which was attributed to the impairment in osteoclast function (7). Therefore, the high bone mass phenotype may result from both enhanced osteoblast and impaired osteocla...

Activation of heterodimeric E2F-DP transcription factors can drive the G 1 -S transition. Mutation of the Drosophila melanogaster dE2F gene eliminates transcriptional activation of several replication factors at the G 1 -S transition and compromises DNA replication. Here we describe a mutation in the Drosophila dDP gene. As expected for a defect in the dE2F partner, this mutation blocks G 1 -S transcription of DmRNR2 and cyclin E as previously described for mutations of dE2F. Mutation of dDP also causes an incomplete block of DNA replication. When S phase is compromised by reducing the activity of dE2F-dDP by either a dE2F or dDP mutation, the first phenotype detected is a reduction in the intensity of BrdU incorporation and a prolongation of the labeling. Notably, in many cells, there was no detected delay in entry into this compromised S phase. In contrast, when cyclin E function was reduced by a hypomorphic allele combination, BrdU incorporation was robust but the timing of S-phase entry was delayed. We suggest that dE2F-dDP contributes to the expression of two classes of gene products: replication factors, whose abundance has a graded effect on replication, and cyclin E, which triggers an all-or-nothing transition from G 1 to S phase.One of the key points of cell cycle regulation is the transition from G 1 into S phase (50, 58). Despite the identification of a number of the regulators that influence this transition, we do not fully understand how it is controlled. Detailed analyses of the phenotypes of mutations in the genes that regulate the transition might provide more insight into the nature of the decisive events that trigger the onset of DNA replication. Such analyses of Saccharomyces cerevisiae have demonstrated two types of phenotypes when entry into S phase is partially compromised (40, 55). Defects in some genes do not delay the transition into S phase but prolong S phase, apparently by reducing replication efficiency. Defects in other genes appear to have an all-or-nothing effect on a decisive event that is presumed to represent a switch from the G 1 to the S-phase states. Analysis of the behavior of cells in other organisms (26) and of nuclei replicating in Xenopus laevis in vitro extracts (39) suggests that an all-or-nothing switch is generally associated with the G 1 -to-S transition.Several findings argue for the importance of the activation of transcription of specific genes that accompanies the G 1 -S transition. Chief among these is the finding that activation of specific transcription factors appears to occur immediately upstream of the decisive transition into S phase in yeast (1, 5), Drosophila melanogaster (15, 17), and mammalian cells (37,44). These factors stimulate a program of expression of genes whose products are required for DNA replication. However, because at least some of the required products are stable and are present as a result of earlier expression, the activation of this gene expression does not necessarily provide direct coupling between replication factor transcription...

No abstract

No abstract

No abstract